All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) metastasis (lung) metastasis (lymph node ) PD-L1 < 1% PD-L1 > 1% stage II stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
breast cancer - triple negative, immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpassion-031 (all population), 2020 0.69 [0.25; 1.89]
IMpassion-130 (all population), 2018 0.86 [0.72; 1.02]
IMpassion-130 (PDL1>1%), 2018 0.71 [0.54; 0.94]
KEYNOTE-119 (all population), 2019 0.97 [0.82; 1.15]
KEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07]
KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06]
KEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05]
KEYNOTE-355 (CPS>1), 2020 0.86 [0.72; 1.03]
KEYNOTE-355 (CPS>10), 2020 0.73 [0.56; 0.96]
0.86 [0.80 ; 0.92 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 9 0% 4,631 low serious deaths (OS) (extension)detailed results GeparNuevo, 2019 0.24 [0.03; 2.28]
0.24 [0.03 ; 2.28 ] GeparNuevo, 2019 1 0% 174 NA not evaluable PFS (extension)detailed results IMpassion-130 (all population), 2018 0.80 [0.69; 0.92]
IMpassion-130 (PDL1>1%), 2018 0.63 [0.50; 0.80]
0.72 [0.57 ; 0.91 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018 2 65% 1,271 low not evaluable progression or deaths (PFS)detailed results IMpassion-130 (all population), 2018 0.80 [0.69; 0.92]
IMpassion-130 (PDL1>1%), 2018 0.62 [0.49; 0.78]
KEYNOTE-119 (all population), 2019 1.60 [1.33; 1.92]
KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68]
KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59]
KEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97]
KEYNOTE-355 (CPS>1), 2020 0.75 [0.62; 0.91]
KEYNOTE-355 (CPS>10), 2020 0.66 [0.50; 0.88]
0.92 [0.72 ; 1.16 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 8 91% 4,298 low not evaluable DCRdetailed results KEYNOTE-119 (all population), 2019 0.60 [0.39; 0.94]
0.60 [0.39 ; 0.94 ] KEYNOTE-119 (all population), 2019 1 0% 622 NA not evaluable DORdetailed results IMpassion-130 (all population), 2018 0.78 [0.63; 0.97]
IMpassion-130 (PDL1>1%), 2018 0.60 [0.42; 0.85]
0.71 [0.55 ; 0.91 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018 2 36% 369 low not evaluable events or deaths (EFS)detailed results IMpassion-031 (all population), 2020 0.76 [0.40; 1.44]
KEYNOTE-522, 2020 0.63 [0.43; 0.93]
0.66 [0.48 ; 0.92 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,507 low not evaluable objective responses (ORR)detailed results IMpassion-130 (all population), 2018 1.52 [1.17; 1.98]
IMpassion-130 (PDL1>1%), 2018 1.96 [1.29; 2.98]
KEYNOTE-119 (all population), 2019 0.89 [0.53; 1.50]
KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54]
KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04]
KEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33]
KEYNOTE-355 (CPS>1), 2020 1.28 [0.92; 1.80]
KEYNOTE-355 (CPS>10), 2020 1.62 [1.01; 2.60]
1.16 [0.65 ; 2.07 ] IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 8 94% 4,298 low not evaluable pCR detailed results GeparNuevo, 2019 1.45 [0.80; 2.63]
IMpassion-031 (all population), 2020 1.95 [1.26; 3.01]
IMpassion-031 (PDL1>1%), 2020 2.23 [1.16; 4.30]
KEYNOTE-522, 2020 13.60 [6.77; 27.33]
2.98 [1.24 ; 7.19 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-031 (PDL1>1%), 2020, KEYNOTE-522, 2020 4 89% 1,263 low not evaluable AE (any grade)detailed results IMpassion-031 (all population), 2020 0.49 [0.02; 14.69]
IMpassion-130 (all population), 2018 3.15 [0.85; 11.73]
KEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87]
KEYNOTE-522, 2020 0.25 [0.01; 4.74]
1.47 [0.63 ; 3.40 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 5% 3,234 low not evaluable AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.10 [0.71; 1.72]
IMpassion-130 (all population), 2018 1.31 [1.00; 1.70]
KEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76]
KEYNOTE-522, 2020 1.35 [1.01; 1.80]
1.28 [1.09 ; 1.50 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 0% 3,234 low not evaluable AE leading to death (grade 5)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
IMpassion-130 (all population), 2018 1.94 [0.48; 7.81]
1.61 [0.49 ; 5.27 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpassion-031 (all population), 2020 1.18 [0.70; 2.01]
IMpassion-130 (all population), 2018 2.24 [1.46; 3.43]
1.66 [0.89 ; 3.11 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 71% 1,221 low not evaluable SAE (any grade)detailed results GeparNuevo, 2019 0.88 [0.47; 1.66]
IMpassion-031 (all population), 2020 2.00 [1.20; 3.36]
IMpassion-130 (all population), 2018 1.33 [0.96; 1.84]
KEYNOTE-119 (all population), 2019 0.99 [0.66; 1.48]
1.25 [0.91 ; 1.70 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-119 (all population), 2019 4 48% 1,996 low not evaluable STRAE (any grade)detailed results IMpassion-031 (all population), 2020 1.58 [0.91; 2.75]
IMpassion-130 (all population), 2018 1.82 [1.16; 2.87]
1.72 [1.21 ; 2.45 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable TRAE (any grade)detailed results IMpassion-031 (all population), 2020 0.98 [0.14; 7.05]
IMpassion-130 (all population), 2018 1.80 [0.96; 3.39]
KEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70]
KEYNOTE-522, 2020 0.25 [0.03; 2.00]
1.38 [0.84 ; 2.27 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 11% 3,234 low not evaluable TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.15 [0.74; 1.77]
IMpassion-130 (all population), 2018 1.52 [1.15; 2.01]
KEYNOTE-119 (all population), 2019 0.29 [0.19; 0.43]
KEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44]
KEYNOTE-522, 2020 1.26 [0.96; 1.66]
0.93 [0.56 ; 1.56 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 5 92% 3,835 low not evaluable TRAE leading to death (grade 5)detailed results IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
KEYNOTE-119 (all population), 2019 0.94 [0.37; 2.41]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
KEYNOTE-522, 2020 1.50 [0.16; 14.43]
1.13 [0.51 ; 2.49 ] IMpassion-130 (all population), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 0% 3,504 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-119 (all population), 2019 1.05 [0.42; 2.63]
KEYNOTE-522, 2020 2.16 [1.53; 3.05]
1.72 [0.89 ; 3.31 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 52% 1,771 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
KEYNOTE-522, 2020 10.08 [0.59; 173.00]
3.47 [0.52 ; 23.34 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 3 0% 2,102 low not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51]
KEYNOTE-522, 2020 0.87 [0.36; 2.09]
0.86 [0.41 ; 1.80 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.28 [0.08; 1.01]
KEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71]
KEYNOTE-522, 2020 1.27 [0.91; 1.77]
1.03 [0.65 ; 1.65 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 60% 2,614 low not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.26 [0.28; 5.69]
KEYNOTE-522, 2020 1.40 [0.65; 3.02]
1.37 [0.69 ; 2.72 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Colitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
KEYNOTE-522, 2020 3.51 [0.43; 28.62]
2.02 [0.49 ; 8.26 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 0% 2,945 low not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.48 [0.04 ; 6.30 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-522, 2020 3.51 [0.43; 28.62]
2.02 [0.34 ; 12.03 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Diabetes TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.25 [0.20 ; 7.77 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 3 0% 2,102 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.23 [0.05; 1.10]
KEYNOTE-522, 2020 1.71 [0.63; 4.67]
0.69 [0.10 ; 4.85 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 78% 1,771 low not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.19; 4.72]
KEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82]
KEYNOTE-522, 2020 2.29 [0.94; 5.58]
1.51 [0.84 ; 2.72 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.05 [0.00; 0.79]
KEYNOTE-522, 2020 1.13 [0.82; 1.57]
0.31 [0.01 ; 6.85 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 79% 1,771 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-522, 2020 9.06 [0.52; 156.66]
4.26 [0.42 ; 42.77 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.24 [0.21 ; 7.26 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 0% 2,945 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 8.04 [0.46; 140.38]
8.04 [0.46 ; 140.38 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
KEYNOTE-522, 2020 3.00 [0.15; 59.96]
1.98 [0.38 ; 10.33 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 0% 2,945 low not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.91 [0.57; 6.42]
KEYNOTE-522, 2020 9.67 [1.29; 72.54]
3.49 [0.75 ; 16.21 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 45% 1,771 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02]
KEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48]
KEYNOTE-522, 2020 2.34 [1.13; 4.86]
1.69 [1.05 ; 2.73 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
KEYNOTE-522, 2020 2.53 [0.86; 7.45]
2.24 [0.82 ; 6.15 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.09 [0.01; 1.71]
KEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19]
KEYNOTE-522, 2020 0.76 [0.57; 1.03]
0.78 [0.61 ; 1.00 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 8% 2,614 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60]
KEYNOTE-522, 2020 0.50 [0.01; 25.13]
2.23 [0.32 ; 15.67 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 3 0% 2,102 low not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69]
KEYNOTE-522, 2020 2.64 [1.01; 6.94]
1.77 [0.85 ; 3.67 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 0% 2,614 low not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-522, 2020 7.03 [0.40; 124.15]
3.49 [0.34 ; 35.41 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.01 [0.00; 0.12]
KEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36]
KEYNOTE-522, 2020 1.06 [0.82; 1.38]
0.81 [0.42 ; 1.55 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 3 83% 2,614 low not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.13 [0.02; 1.08]
0.13 [0.02 ; 1.08 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 4.00 [0.21; 75.85]
4.00 [0.21 ; 75.85 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23]
0.24 [0.01 ; 5.23 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.88 [0.62; 5.72]
1.88 [0.62 ; 5.72 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.16 [0.01; 3.13]
KEYNOTE-522, 2020 1.20 [0.42; 3.43]
0.72 [0.13 ; 4.06 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 37% 1,771 low not evaluable Pneumonia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23]
0.24 [0.01 ; 5.23 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60]
KEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78]
KEYNOTE-522, 2020 1.50 [0.16; 14.43]
2.93 [0.72 ; 11.83 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 0% 2,945 low not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
KEYNOTE-522, 2020 4.02 [0.50; 32.22]
2.39 [0.45 ; 12.62 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Rash TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.32; 3.23]
KEYNOTE-522, 2020 3.51 [0.43; 28.62]
1.37 [0.49 ; 3.84 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 2% 1,501 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Sepsis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
0.94 [0.02 ; 47.78 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02]
KEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64]
KEYNOTE-522, 2020 15.50 [2.11; 114.09]
5.90 [1.64 ; 21.16 ] IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-522, 2020 4 0% 2,945 low not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-522, 2020 11.10 [0.65; 189.37]
2.64 [0.12 ; 57.65 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 49% 1,771 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.50 [0.13 ; 17.05 ] KEYNOTE-119 (all population), 2019, KEYNOTE-522, 2020 2 0% 1,771 low not evaluable Urticaria TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.51 [0.59; 3.82]
1.51 [0.59 ; 3.82 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.04; 5.22]
0.47 [0.04 ; 5.22 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
1.23 [0.14 ; 10.62 ] GeparNuevo, 2019, IMpassion-130 (all population), 2018 2 0% 1,064 low not evaluable Abdominal pain AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.16 [0.20 ; 6.72 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Acute kidney injury AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Adrenal insufficiency AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Alopecia AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.43 [0.23 ; 8.79 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Anaemia AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.12; 6.46]
IMpassion-031 (all population), 2020 1.21 [0.54; 2.69]
IMpassion-130 (all population), 2018 1.04 [0.48; 2.24]
1.10 [0.64 ; 1.87 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Arthralgia AE (grade 3-4)detailed results GeparNuevo, 2019 1.80 [0.16; 20.23]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
1.30 [0.25 ; 6.81 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Asthenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.54 [0.25; 9.32]
IMpassion-130 (all population), 2018 0.72 [0.16; 3.24]
0.98 [0.31 ; 3.12 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Back pain AE (grade 3-4)detailed results GeparNuevo, 2019 0.44 [0.01; 13.37]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 2.92 [0.59; 14.54]
1.90 [0.49 ; 7.43 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Blood creatinine increased AE (grade 3-4)detailed results GeparNuevo, 2019 0.05 [0.00; 0.89]
0.05 [0.00 ; 0.89 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Cardiomyopathy AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Chills AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Colitis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.96 [0.06 ; 15.47 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Constipation AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
IMpassion-130 (all population), 2018 2.91 [0.30; 28.05]
1.39 [0.29 ; 6.62 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Cough AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.10 ; 9.23 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Decreased appetite AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.19; 4.80]
0.97 [0.22 ; 4.30 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Diarrhoea AE (grade 3-4)detailed results GeparNuevo, 2019 5.49 [0.27; 111.35]
IMpassion-031 (all population), 2020 4.15 [0.46; 37.53]
IMpassion-130 (all population), 2018 0.85 [0.33; 2.24]
1.58 [0.48 ; 5.16 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 25% 1,395 low not evaluable Dizziness AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dry skin AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
1.43 [0.11 ; 18.75 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Dysgeusia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.99 [0.06 ; 15.89 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 0% 1,221 low not evaluable Dyspepsia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dysphonia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dyspnoea AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.14; 7.32]
IMpassion-130 (all population), 2018 0.96 [0.19; 4.80]
0.98 [0.30 ; 3.20 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Epistaxis AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
0.95 [0.06 ; 15.32 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Fatigue AE (grade 3-4)detailed results GeparNuevo, 2019 0.47 [0.15; 1.45]
IMpassion-031 (all population), 2020 1.23 [0.37; 4.11]
IMpassion-130 (all population), 2018 1.10 [0.54; 2.22]
0.93 [0.54 ; 1.59 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Febrile neutropenia AE (grade 3-4)detailed results GeparNuevo, 2019 1.82 [0.32; 10.20]
IMpassion-031 (all population), 2020 1.25 [0.61; 2.57]
1.32 [0.68 ; 2.57 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Headache AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
IMpassion-130 (all population), 2018 0.48 [0.09; 2.63]
0.60 [0.15 ; 2.42 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 3 0% 1,395 low not evaluable Hypertension AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.84 [0.35; 2.00]
IMpassion-130 (all population), 2018 0.35 [0.11; 1.09]
0.59 [0.25 ; 1.38 ] IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018 2 31% 1,221 low not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-02 07:38 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 324,142,305,306,98,96,269,60,143,270,140,240
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
